{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:16:35Z","timestamp":1791908195498,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:00:00Z","timestamp":1574035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:00:00Z","timestamp":1574035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Achieving biochemical control (normalization of insulin-like growth factor-1 [IGF-1] and growth hormone [GH]) is a key goal in acromegaly management. However, IGF-1 and GH fluctuate over time. The true potential impact of time-varying biochemical control status on comorbidities is unclear and relies on multiple, longitudinal IGF-1 and GH measurements. This study assessed the association between time-varying biochemical control status and onset of selected comorbidities in patients with acromegaly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medical charts of adults with confirmed acromegaly and \u2265\u20096\u00a0months of follow-up at an Italian endocrinology center were reviewed. Patients were followed from the first diagnosis of acromegaly at the center until loss to follow-up, chart abstraction, or death. Biochemical control status was assessed annually and defined as IGF-1 \u2264 the upper limit of normal, or\u00a0GH\u2009\u2264\u20092.5\u00a0\u00b5g\/L in the few cases where IGF-1 was unavailable.\u00a0Time-varying Cox models were used to assess the association between biochemical control status and comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 150 patients, 47% were female, average age at diagnosis was 43.1, and mean length of follow-up was 10.4\u00a0years. Biochemical control was significantly associated with a lower hazard of diabetes (HR\u2009=\u20090.36, 95% CI 0.15; 0.83) and cardiovascular system disorders (HR\u2009=\u20090.54, 95% CI 0.31; 0.93), and a higher hazard of certain types of arthropathy (HR\u2009=\u20091.68, 95% CI 1.04; 2.71); associations for other comorbidities did not reach statistical significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Results further support the importance of achieving biochemical control, as this may reduce the risk of high-burden conditions, including diabetes and cardiovascular system disorders. The association for arthropathy suggests irreversibility of this impairment. Due to limitations, caution is required when interpreting these results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-019-01138-y","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T14:02:41Z","timestamp":1574085761000},"page":"529-538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study"],"prefix":"10.1007","volume":"43","author":[{"given":"A.","family":"Colao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. F. S.","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Di Cera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9047-3941","authenticated-orcid":false,"given":"P.","family":"Thompson-Leduc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. C.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P.","family":"Neary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Pedroncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Maamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,18]]},"reference":[{"issue":"11","key":"1138_CR1","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson\u00a0L,\u00a0Laws ER Jr,\u00a0Melmed S,\u00a0Molitch ME,\u00a0Murad MH,\u00a0Utz A,\u00a0Wass JA,\u00a0Endocrine\u00a0Society (2014) Acromegaly: an\u00a0endocrine\u00a0society\u00a0clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1138_CR2","doi-asserted-by":"publisher","first-page":"R59","DOI":"10.1530\/ec-15-0064","volume":"4","author":"JM Silverstein","year":"2015","unstructured":"Silverstein JM (2015) Need for improved monitoring in patients with acromegaly. Endocr Connect 4(4):R59\u2013R67. https:\/\/doi.org\/10.1530\/ec-15-0064","journal-title":"Endocr Connect"},{"issue":"1","key":"1138_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","volume":"5","author":"A Colao","year":"2019","unstructured":"Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, Pivonello R (2019) Acromegaly. Nat Rev Dis Primers 5(1):20. https:\/\/doi.org\/10.1038\/s41572-019-0071-6","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1138_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1530\/eje-08-0267","volume":"159","author":"IM Holdaway","year":"2008","unstructured":"Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159(2):89\u201395. https:\/\/doi.org\/10.1530\/eje-08-0267","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1138_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1210\/jc.2003-031199","volume":"89","author":"IM Holdaway","year":"2004","unstructured":"Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2):667\u2013674. https:\/\/doi.org\/10.1210\/jc.2003-031199","journal-title":"J Clin Endocrinol Metab"},{"key":"1138_CR6","unstructured":"Mayo clinic (2018) Acromegaly. https:\/\/www.mayoclinic.org\/diseases-conditions\/acromegaly\/diagnosis-treatment\/drc-20351226. Accessed 14 Sep 2018"},{"issue":"Suppl 4","key":"1138_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP.17.S4.1","volume":"17","author":"L Katznelson","year":"2011","unstructured":"Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK, American Association of Clinical E (2011) American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly\u20132011 update. Endocr Pract 17(Suppl 4):1\u201344","journal-title":"Endocr Pract"},{"issue":"4","key":"1138_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1530\/EJE-14-0844","volume":"172","author":"C Schofl","year":"2015","unstructured":"Schofl C, Grussendorf M, Honegger J, Tonjes A, Thyroke-Gronostay D, Mayr B, Schopohl J, Participants of German Acromegaly R (2015) Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey. Eur J Endocrinol 172(4):351\u2013356. https:\/\/doi.org\/10.1530\/EJE-14-0844","journal-title":"Eur J Endocrinol"},{"key":"1138_CR9","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.2147\/PPA.S102302","volume":"10","author":"EA Christofides","year":"2016","unstructured":"Christofides EA (2016) Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly. Patient Prefer Adherence 10:1217\u20131225. https:\/\/doi.org\/10.2147\/PPA.S102302","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"1138_CR10","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1210\/jc.2013-3757","volume":"99","author":"JD Carmichael","year":"2014","unstructured":"Carmichael JD, Bonert VS, Nuno M, Ly D, Melmed S (2014) Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab 99(5):1825\u20131833. https:\/\/doi.org\/10.1210\/jc.2013-3757","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1138_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12902-017-0166-6","volume":"17","author":"JD Carmichael","year":"2017","unstructured":"Carmichael JD, Broder MS, Cherepanov D, Chang E, Mamelak A, Said Q, Neary MP, Bonert V (2017) The association between biochemical control and cardiovascular risk factors in acromegaly. BMC Endocr Disord 17(1):15. https:\/\/doi.org\/10.1186\/s12902-017-0166-6","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"1138_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1530\/EJE-12-0084","volume":"167","author":"M Arosio","year":"2012","unstructured":"Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, Pivonello R, Grottoli S, Losa M, Cannavo S, Minuto F, Montini M, Bondanelli M, De Menis E, Martini C, Angeletti G, Velardo A, Peri A, Faustini-Fustini M, Tita P, Pigliaru F, Borretta G, Scaroni C, Bazzoni N, Bianchi A, Appetecchia M, Cavagnini F, Lombardi G, Ghigo E, Beck-Peccoz P, Colao A, Terzolo M, Italian Study Group of A (2012) Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 167(2):189\u2013198. https:\/\/doi.org\/10.1530\/EJE-12-0084","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1138_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1530\/EJE-16-0117","volume":"175","author":"J Dal","year":"2016","unstructured":"Dal J, Feldt-Rasmussen U, Andersen M, Kristensen LO, Laurberg P, Pedersen L, Dekkers OM, Sorensen HT, Jorgensen JO (2016) Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol 175(3):181\u2013190. https:\/\/doi.org\/10.1530\/EJE-16-0117","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"1138_CR14","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1210\/jc.2016-1937","volume":"101","author":"LA Portocarrero-Ortiz","year":"2016","unstructured":"Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, Uribe-Diaz AM, Garcia-Dominguez A, Reza-Albarran AA, Cuevas-Ramos D, Melgar V, Talavera J, Rivera-Hernandez AJ, Valencia-Mendez CV, Mercado M, Mexican Acromegaly Registry G (2016) The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab 101(11):3997\u20134004. https:\/\/doi.org\/10.1210\/jc.2016-1937","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1138_CR15","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1210\/jc.2014-2670","volume":"99","author":"M Mercado","year":"2014","unstructured":"Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E, Jervis P, Roldan P, Mendoza V, Lopez-Felix B, Guinto G (2014) Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab 99(12):4438\u20134446. https:\/\/doi.org\/10.1210\/jc.2014-2670","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1138_CR16","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1210\/jc.2013-2450","volume":"99","author":"M Sherlock","year":"2014","unstructured":"Sherlock M, Reulen RC, Aragon-Alonso A, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM (2014) A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk. J Clin Endocrinol Metab 99(2):478\u2013485. https:\/\/doi.org\/10.1210\/jc.2013-2450","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1138_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1365-2265.2011.04019.x","volume":"75","author":"CN Jayasena","year":"2011","unstructured":"Jayasena CN, Comninos AN, Clarke H, Donaldson M, Meeran K, Dhillo WS (2011) The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin Endocrinol (Oxf) 75(2):220\u2013225. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04019.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1138_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s11102-015-0700-3","volume":"19","author":"L Varadhan","year":"2016","unstructured":"Varadhan L, Reulen RC, Brown M, Clayton RN (2016) The role of cumulative growth hormone exposure in determining mortality and morbidity in acromegaly: a single centre study. Pituitary 19(3):251\u2013261. https:\/\/doi.org\/10.1007\/s11102-015-0700-3","journal-title":"Pituitary"},{"issue":"3","key":"1138_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/clc.22867","volume":"41","author":"AN Sharma","year":"2018","unstructured":"Sharma AN, Tan M, Amsterdam EA, Singh GD (2018) Acromegalic cardiomyopathy: epidemiology, diagnosis, and management. Clin Cardiol 41(3):419\u2013425. https:\/\/doi.org\/10.1002\/clc.22867","journal-title":"Clin Cardiol"},{"issue":"5","key":"1138_CR20","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/j.ijcard.2012.11.109","volume":"167","author":"S Mosca","year":"2013","unstructured":"Mosca S, Paolillo S, Colao A, Bossone E, Cittadini A, Iudice FL, Parente A, Conte S, Rengo G, Leosco D, Trimarco B, Filardi PP (2013) Cardiovascular involvement in patients affected by acromegaly: an appraisal. Int J Cardiol 167(5):1712\u20131718. https:\/\/doi.org\/10.1016\/j.ijcard.2012.11.109","journal-title":"Int J Cardiol"},{"key":"1138_CR21","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fendo.2018.00358","volume":"9","author":"F Ferrau","year":"2018","unstructured":"Ferrau F, Albani A, Ciresi A, Giordano C, Cannavo S (2018) Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment. Front Endocrinol (Lausanne) 9:358. https:\/\/doi.org\/10.3389\/fendo.2018.00358","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"1138_CR22","doi-asserted-by":"publisher","first-page":"e0127276","DOI":"10.1371\/journal.pone.0127276","volume":"10","author":"S Cheng","year":"2015","unstructured":"Cheng S, Gomez K, Serri O, Chik C, Ezzat S (2015) The role of diabetes in acromegaly associated neoplasia. PLoS One 10(5):e0127276. https:\/\/doi.org\/10.1371\/journal.pone.0127276","journal-title":"PLoS One"},{"issue":"5","key":"1138_CR23","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1210\/jc.2004-2297","volume":"90","author":"NR Biermasz","year":"2005","unstructured":"Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F (2005) Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 90(5):2731\u20132739. https:\/\/doi.org\/10.1210\/jc.2004-2297","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1138_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1046\/j.1365-2265.1999.00851.x","volume":"51","author":"A Colao","year":"1999","unstructured":"Colao A, Marzullo P, Vallone G, Giaccio A, Ferone D, Rossi E, Scarpa R, Smaltino F, Lombardi G (1999) Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12\u00a0months. Clin Endocrinol (Oxf) 51(5):611\u2013618. https:\/\/doi.org\/10.1046\/j.1365-2265.1999.00851.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1138_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1530\/eje.0.1480031","volume":"148","author":"A Colao","year":"2003","unstructured":"Colao A, Cannavo S, Marzullo P, Pivonello R, Squadrito S, Vallone G, Almoto B, Bichisao E, Trimarchi F, Lombardi G (2003) Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. Eur J Endocrinol 148(1):31\u201338. https:\/\/doi.org\/10.1530\/eje.0.1480031","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1138_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1530\/EJE-12-0147","volume":"167","author":"KM Claessen","year":"2012","unstructured":"Claessen KM, Ramautar SR, Pereira AM, Smit JW, Roelfsema F, Romijn JA, Kroon HM, Kloppenburg M, Biermasz NR (2012) Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. Eur J Endocrinol 167(2):235\u2013244. https:\/\/doi.org\/10.1530\/EJE-12-0147","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1138_CR27","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1210\/jc.2013-2695","volume":"98","author":"KM Claessen","year":"2013","unstructured":"Claessen KM, Kroon HM, Pereira AM, Appelman-Dijkstra NM, Verstegen MJ, Kloppenburg M, Hamdy NA, Biermasz NR (2013) Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. J Clin Endocrinol Metab 98(12):4808\u20134815. https:\/\/doi.org\/10.1210\/jc.2013-2695","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1138_CR28","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s10067-013-2219-1","volume":"32","author":"LL Kropf","year":"2013","unstructured":"Kropf LL, Madeira M, Vieira Neto L, Gadelha MR, de Farias ML (2013) Functional evaluation of the joints in acromegalic patients and associated factors. Clin Rheumatol 32(7):991\u2013998. https:\/\/doi.org\/10.1007\/s10067-013-2219-1","journal-title":"Clin Rheumatol"},{"issue":"2","key":"1138_CR29","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/ard.2010.131698","volume":"70","author":"MJ Wassenaar","year":"2011","unstructured":"Wassenaar MJ, Biermasz NR, Bijsterbosch J, Pereira AM, Meulenbelt I, Smit JW, Roelfsema F, Kroon HM, Romijn JA, Kloppenburg M (2011) Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. Ann Rheum Dis 70(2):320\u2013325. https:\/\/doi.org\/10.1136\/ard.2010.131698","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1138_CR30","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1242\/dev.110.4.1233","volume":"110","author":"EJ Mackie","year":"1990","unstructured":"Mackie EJ, Trechsel U, Bruns C (1990) Somatostatin receptors are restricted to a subpopulation of osteoblast-like cells during endochondral bone formation. Development 110(4):1233\u20131239","journal-title":"Development"},{"issue":"2","key":"1138_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40618-018-0905-1","volume":"42","author":"M Demirpence","year":"2019","unstructured":"Demirpence M, Guler A, Yilmaz H, Sayin A, Pekcevik Y, Turkon H, Colak A, Ari EM, Aslanipour B, Kocabas GU, Calan M (2019) Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly? J Endocrinol Invest 42(2):207\u2013215. https:\/\/doi.org\/10.1007\/s40618-018-0905-1","journal-title":"J Endocrinol Invest"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01138-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-019-01138-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01138-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T20:16:59Z","timestamp":1665001019000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-019-01138-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,18]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1138"],"URL":"https:\/\/doi.org\/10.1007\/s40618-019-01138-y","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736937718.793576606","asserted-by":"object"}]},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,18]]},"assertion":[{"value":"9 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AC declares the following potential conflict of interest: Novartis, Pfizer, Sandoz. RP declares the following potential conflicts of interest: Novartis, Pfizer, Viropharma-Shire, Ferring, Italfarmaco, Ipsen, IBSA, HRA Pharma. MN, AP, and RM are employees and former employees of Novartis. WYC, PTL, HCC, and MSD are employees of Analysis Group, Inc., a consulting firm that was hired by Novartis for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}